Tibsovo OverviewIvosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. The drug is being developed by Agios Pharmaceuticals and is in phase III clinical trials.[when?] The U.S. Food and Drug Administration (FDA) awarded orphan drug designation for acute myeloid leukemia and cholangiocarcinoma. In 2018, ivosidenib was approved in the Uni...
Read more Tibsovo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ivosidenib
Recent Tibsovo Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 250mg
NDC Database Records for Tibsovo: (1 result)Sorted by National Drug Code
- 71334-100 Tibsovo 250 mg Oral Tablet, Film Coated by Agios Pharmaceuticals, Inc.